Neurology · Sleep Disorders
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
The diagnosis of Restless Legs Syndrome (RLS) is primarily clinical, characterized by an urge to move the legs that is typically accompanied by unpleasant sensations.
Symptoms of RLS are classically worsened by rest or inactivity and are relieved by movement such as walking or stretching.
RLS symptoms follow a circadian rhythm, exhibiting a distinct diurnal variation with worsening severity in the evening or at night.
The initial laboratory evaluation for all patients with suspected RLS must include a serum ferritin level to screen for iron deficiency.
First-line pharmacologic therapy for patients with persistent, moderate-to-severe RLS is an alpha-2-delta ligand (gabapentinoid) such as gabapentin enacarbil, gabapentin, or pregabalin; non-ergot dopamine agonists (pramipexole, ropinirole) are no longer preferred due to augmentation.
Patients with RLS and a serum ferritin level < 75 ng/mL (or transferrin saturation <45%) should be treated with oral iron supplementation to improve symptoms.
Dopamine agonists carry a risk of augmentation, a phenomenon where symptoms occur earlier in the day, increase in intensity, or spread to other body parts.
Vignette unlocked
A 54-year-old woman presents to the clinic complaining of unpleasant, creeping sensations in her lower extremities that make it difficult to fall asleep. She notes that these symptoms are relieved by walking around her bedroom at night. She has no history of diabetes or peripheral neuropathy. Her physical examination is unremarkable, and her serum ferritin is 35 ng/mL.
What is the most appropriate initial management for this patient?
Oral iron supplementation
The patient meets the clinical criteria for RLS, and because her ferritin is below the threshold of 75 ng/mL, iron replacement is the first-line intervention before initiating dopamine agonists.
Full handout
High yield triage
Etiology / Epidemiology
Associated with iron deficiency and uremia. Common in pregnancy and elderly patients.
Clinical Manifestations
Urge to move legs with unpleasant sensations relieved by movement, worsening at night.
Diagnosis
Clinical diagnosis based on IRLSSG criteria. Check serum ferritin levels.
Treatment
Gabapentinoids (gabapentin enacarbil, gabapentin, pregabalin) are first-line; dopamine agonists are no longer preferred. Augmentation is a major risk.
Prognosis
Chronic condition causing insomnia and significant impaired quality of life.
Full handout
Epidemiology & Etiology
Prevalence increases with age and is higher in women. Primary causes are often idiopathic, while secondary causes include iron deficiency anemia, end-stage renal disease, and pregnancy. Certain medications like SSRIs and antipsychotics can exacerbate symptoms.
Pertinent Anatomy
Symptoms typically involve the lower extremities, specifically the calves. The pathophysiology involves the dopaminergic system within the basal ganglia. Peripheral sensory input from the legs triggers the urge to move.
Pathophysiology
The core mechanism involves dopaminergic dysfunction and impaired iron metabolism in the substantia nigra. Iron is a necessary cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. Low brain iron leads to decreased dopaminergic transmission, manifesting as motor restlessness.
Clinical Manifestations
Patients report paresthesias or dysesthesias described as crawling or pulling sensations. Symptoms follow a circadian rhythm, peaking in the evening or at night. Red flags include sudden onset or neurological deficits, which suggest peripheral neuropathy or radiculopathy.
Diagnosis
Diagnosis is clinical using the IRLSSG criteria: urge to move, onset at rest, relief with activity, and evening worsening. Serum ferritin < 75 mcg/L is a critical threshold for iron replacement. No specific imaging is required, but polysomnography may show periodic limb movements of sleep.
Treatment
First-line therapy includes alpha-2-delta ligands like gabapentin enacarbil, gabapentin, or pregabalin. Augmentation—the worsening of symptoms earlier in the day—is a common complication of long-term agonist use. If ferritin is low, oral iron supplementation is mandatory. Gabapentin or pregabalin are alternatives for patients with comorbid pain.
Prognosis
The condition is chronic and progressive, leading to severe sleep deprivation. Patients require long-term monitoring for augmentation and medication side effects. Quality of life scores are significantly lower in untreated patients.
Differential Diagnosis
Peripheral neuropathy: constant symptoms not relieved by movement
Leg cramps: sudden, painful muscle contractions without the urge to move
Akathisia: generalized inner restlessness not limited to the legs
Arthritis: pain associated with joint movement rather than rest
Venous insufficiency: symptoms associated with edema and skin changes